{"id":1754,"date":"2009-12-01T12:08:00","date_gmt":"2009-12-01T11:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/leserbrief-27"},"modified":"2009-12-01T12:08:00","modified_gmt":"2009-12-01T11:08:00","slug":"leserbrief-27","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/leserbrief-27","title":{"rendered":"Leserbrief"},"content":{"rendered":"<p>Ein Leser wehrt sich gegen Pharmareferenten Viele \u00c4rztinnen und \u00c4rzte haben in den vergangenen Wochen mit der Post oder von Pharmareferenten der Firma Boehringer Ingelheim einen Sonderdruck aus dem N. Engl. J. Med. erhalten: \u201eDabigatran versus Warfarin in Patients with Atrial Fibrillation\u201d (1). Einer unserer Leser verbittet sich diese einseitige Information und verdeckte Werbung und [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ein Leser wehrt sich gegen Pharmareferenten Viele \u00c4rztinnen und \u00c4rzte haben in den vergangenen Wochen mit der Post oder von Pharmareferenten der Firma Boehringer Ingelheim einen Sonderdruck aus dem N. Engl. J. Med. erhalten: \u201eDabigatran versus Warfarin in Patients with Atrial Fibrillation\u201d (1). Einer unserer Leser verbittet sich diese einseitige Information und verdeckte Werbung und [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,2305,1314,1312,1328,1327,3918,1561],"class_list":["post-1754","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-neue-orale-antikoagulanzien","tag-noak","tag-pharmareferenten","tag-werbung"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1754"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1754\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}